GRCE - mixed-signals-high-insider-ownership-amid-negative-profitability

Deep-Dive Due Diligence AI Generated Report on Grace Therapeutics, Inc. Common Stock (GRCE)

Welcome to ScanScor. What you're reading is not just a stock summary -- it's a real-time, AI-generated due diligence session crafted from live news, financial data, insider trading activity, SEC filings, and live market momentum.

These reports are generated using OpenAI's GPT-based analysis engine, guided by tightly structured prompts and expert-level data ingestion. Every insight below was assembled to help you understand the forces behind today's market movers.

Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.

GRCE_OUT_1 [2025-03-19 15:34:24 -0400] 2073 Bytes | 569 tokens | Cum: 569 tkns (7.11% of 8k)
==========================================================================

We are in the 'Lightning Round' baby! It's 03:34:22 PM on Wednesday March 19, 2025 ET (UTC-0400), and I'm firing up the spotlight on Grace Therapeutics (GRCE), moving from 2.33 to 2.68. Is this a can’t-miss rocket or a one-hit wonder? Let’s dissect the numbers!

Here's the first list of news for Grace Therapeutics:

C1 - Mar-11-25 07:00AM - Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
C2 - Feb-25-25 08:00AM - Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
C3 - Feb-13-25 08:00AM - Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update
C4 - Feb-11-25 10:26AM - Grace Therapeutics secures $15m for GTx-104 pre-commercial development
C5 - Feb-10-25 12:05PM - Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study
C6 - Feb-10-25 12:05PM 08:05AM - Grace Therapeutics Announces Private Placement Financing of up to $30 Million
C7 - Feb-10-25 12:05PM 08:01AM - Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH
C8 - Jan-07-25 08:00AM - Grace Therapeutics to Participate in Upcoming Investor Events January 2025

ONLY 3 RULES for AI:
==============
1) This is a document retrieval system. You are the analyst-investigator.
2) You can request items from any list to get more details about Grace Therapeutics (GRCE)
3) AFTER requesting and reading News and SEC filings you'll get tokens to write a summary, set a score and high price target, and finally take an exit quiz.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.

Thank you for your analysis of Grace Therapeutics.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!

Please request a document, read, summarize and score. Say something like "C1".

GRCE_IN_2 [2025-03-19 15:34:24 -0400] 2 Bytes | 2 tokens | Cum: 571 tkns (7.14% of 8k)
==========================================================================

GRCE_OUT_3 [2025-03-19 15:34:31 -0400] 970 Bytes | 247 tokens | Cum: 818 tkns (10.22% of 8k)
==========================================================================

Showing C5 (chunk 1 of 4): C5:
**Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study**
Date: Feb-10-25 12:05PM
Source: (Benzinga)
URL: https://finance.yahoo.com/news/small-cap-grace-therapeutics-touts-170559950.html

On Monday,Grace Therapeutics, Inc.(NASDAQ:GRCE), formerly b, announced topline data from its Phase 3 STRIVE-ON safety trial of GTx-104 compared with oral nimodipine in patients hospitalized with aneurysmalSubarachnoid Hemorrhage (aSAH).

aSAH is bleeding over the brain’s surface in the subarachnoid space between the brain and the skull, which contains blood vessels that supply the brain.

The study met its primary endpoint and provides evidence of clinical benefit compared to orally administered nimodipine.

The trial met its primary endpoint, with patients receiving GTx-104 observed to have a 19% reduction in at least one incidence of clinically significant hypotension compar

-- More? (MOR) or Next section? (NEX)

GRCE_IN_4 [2025-03-19 15:34:31 -0400] 505 Bytes | 113 tokens | Cum: 931 tkns (11.64% of 8k)
==========================================================================

The small-cap company Grace Therapeutics announced positive topline data from its Phase 3 STRIVE-ON safety trial of GTx-104 compared to the orally administered nimodipine in patients with aneurysmal Subarachnoid Hemorrhage (aSAH). The trial met its primary endpoint, showing that patients receiving GTx-104 had a 19% reduction in at least one incidence of clinically significant hypotension. This data suggests that GTx-104 could potentially be more effective than the current standard treatment for aSAH.

GRCE_OUT_5 [2025-03-19 15:34:41 -0400] 970 Bytes | 235 tokens | Cum: 1166 tkns (14.57% of 8k)
==========================================================================

Showing C5 (chunk 2 of 4): ed to oral nimodipine (28% versus 35%). Other measures also favored or were comparable to GTx-104, including:

54% of patients who received GTx-104 had a relative dose intensity (RDI) of 95% or higher of the prescribed dose compared to only 8% on oral nimodipine.

29% relative increase in the number of patients receiving GTx-104 compared to oral nimodipine with favorable outcomes at 90 days follow-up on the modified Rankin scale.

Fewer intensive care unit (ICU) readmissions, ICU days, and ventilator days for patients receiving GTx-104 versus oral nimodipine.

Adverse events were comparable between the two arms and no new safety issues were identified with patients receiving GTx-104. All deaths in both arms of the trial were due to the severity of the patient’s underlying disease.

US new drug application submission is expected in the first half of 2025.

Concurrently, Grace Therapeutics

-- More? (MOR) or Next section? (NEX)

GRCE_IN_6 [2025-03-19 15:34:41 -0400] 1135 Bytes | 218 tokens | Cum: 1384 tkns (17.30% of 8k)
==========================================================================

From a financial perspective, this data suggests that GTx-104 may have considerable market potential, which could potentially lead to increased revenue and profitability for Grace Therapeutics. The drug demonstrated improved patient outcomes, fewer ICU readmissions, and fewer ICU and ventilator days compared to oral nimodipine. Furthermore, a higher percentage of patients were able to reach a relative dose intensity of 95% or higher with GTx-104 compared to oral nimodipine. This could mean reduced treatment costs and lower healthcare expenditure in the long term.

However, it's important to consider the potential risks and challenges. The company's new drug application submission is expected in the first half of 2025, which means there are still regulatory hurdles to pass. Moreover, the safety profile of GTx-104 should be closely monitored as all deaths in both arms of the trial were due to the severity of the patient’s underlying disease.

Overall, the financial outlook for the drug and Grace Therapeutics seems positive, but further analysis and monitoring is required as the drug advances in the approval process.

GRCE_OUT_7 [2025-03-19 15:34:43 -0400] 968 Bytes | 226 tokens | Cum: 1610 tkns (20.12% of 8k)
==========================================================================

Showing C5 (chunk 3 of 4): announced a private placement of approximately $30 million consisting of initial upfront funding of approximately $15.0 million and the potential to receive up to an additional approximately $15.0 million upon cash exercise of accompanying warrants atthe election of the investors.

Grace Therapeutics will issue an aggregate of 4.42 million common shares and accompanying common warrants to purchase up to 4.42 million at a combined purchase price of $3.395.

Grace Therapeutics will use the net proceeds to fund the development of GTx-104.

Price Action:GRCE stock is up 4.32% at $3.38 at last check Monday.

Hyatt Expands All-Inclusive Empire With $2.6 Billion Playa Deal: Asset-Light Strategy In Focus

UNLOCKED: 5 NEW TRADES EVERY WEEK.Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.

This articleSmall-Cap Grac

-- More? (MOR) or Next section? (NEX)

GRCE_IN_8 [2025-03-19 15:34:43 -0400] 3 Bytes | 2 tokens | Cum: 1612 tkns (20.15% of 8k)
==========================================================================

NEX

GRCE_OUT_9 [2025-03-19 15:34:45 -0400] 969 Bytes | 281 tokens | Cum: 1893 tkns (23.66% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-11T12:07:47Z - Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors...
A2 - 2025-03-11T11:12:47Z - Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors | Taiwan News | Mar. 11, 2...
A3 - 2025-03-11T11:13:14Z - Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors - Grace Therapeutics (NASD...
A4 - 2025-03-11T11:07:14Z - Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors...
A5 - 2025-02-25T13:23:19Z - Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

GRCE_IN_10 [2025-03-19 15:34:45 -0400] 2 Bytes | 2 tokens | Cum: 1895 tkns (23.69% of 8k)
==========================================================================

GRCE_OUT_11 [2025-03-19 15:34:46 -0400] 968 Bytes | 269 tokens | Cum: 2164 tkns (27.05% of 8k)
==========================================================================

Showing A1 (chunk 1 of 11): A1:
**Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors**Date: 2025-03-11Source: {'uri': 'manilatimes.net', 'dataType': 'news', 'title': 'The Manila times'}URL: https://www.manilatimes.net/2025/03/11/tmt-newswire/globenewswire/matinas-biopharma-appoints-seasoned-biotech-leaders-to-board-of-directors/2070987Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the "Effective Date"). In addition, Matthew Wikler, M.D., and Natasha Giordano stepped down from the Board on the Effective Date.

"We are thrilled to announce the addition of K

-- More? (MOR) or Next section? (NEX)

GRCE_IN_12 [2025-03-19 15:34:47 -0400] 3 Bytes | 2 tokens | Cum: 2166 tkns (27.07% of 8k)
==========================================================================

NEX

GRCE_OUT_13 [2025-03-19 15:34:48 -0400] 394 Bytes | 113 tokens | Cum: 2279 tkns (28.49% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-02-10T13:01:00Z - Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

GRCE_IN_14 [2025-03-19 15:34:48 -0400] 2 Bytes | 2 tokens | Cum: 2281 tkns (28.51% of 8k)
==========================================================================

GRCE_OUT_15 [2025-03-19 15:35:00 -0400] 712 Bytes | 211 tokens | Cum: 2492 tkns (31.15% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/02/10/3023405/0/en/Grace-Therapeutics-Announces-Results-From-Pivotal-Phase-3-STRIVE-ON-Safety-Trial-of-GTx-104-in-aSAH.htmlGrace Therapeutics announced that its Phase 3 STRIVE-ON trial for GTx-104, a novel injectable formulation of nimodipine, met its primary endpoint and showed evidence of clinical benefit over oral nimodipine in aSAH patients. The company plans to submit a New Drug Application (NDA) for GTx-104 in the first half of 2025.

-- More? (MOR) or Next section? (NEX)

GRCE_IN_16 [2025-03-19 15:35:00 -0400] 1104 Bytes | 218 tokens | Cum: 2710 tkns (33.88% of 8k)
==========================================================================

The results from the Phase 3 STRIVE-ON trial for GTx-104 by Grace Therapeutics are quite significant. The fact that the trial met its primary endpoint and showed clinical benefit over oral nimodipine for aSAH patients is promising. This could potentially position GTx-104 as a strong contender in the market for aSAH treatments, pending FDA approval.

The company's plans to submit a New Drug Application in the first half of 2025 should be closely monitored as it could significantly impact Grace Therapeutics' valuation. If approved, the new drug could provide a significant revenue stream for the company.

However, it's also important to consider the risks associated with drug development and approval. There is always a chance that the FDA could reject the NDA or request additional data, which could delay the drug's launch.

In conclusion, while the trial results are a positive development for Grace Therapeutics, investors should closely follow the progress of the NDA submission and potential FDA approval. As with any investment in the biotech sector, there are significant risks and rewards.

GRCE_OUT_17 [2025-03-19 15:35:02 -0400] 1073 Bytes | 285 tokens | Cum: 2995 tkns (37.44% of 8k)
==========================================================================

This is our list of SEC filings.
Read it just by asking.
Don't miss breaking filings!

S1 - 2025-02-13 8-K Item 2.02 Results of Oper and Fin Cond.

The following information is furnished pursuant to Item 2.02 "Results of Oper and Fin Cond."

On February 13, 2025, Grace Therapeutics, Inc. (formerly Acasti Pharma Inc.) issued a press release announcing ...

S2 - 2025-02-13 10-Q PART I. FIN INFO

Item 1. Fin Information

Unaudited Condensed Cons Fin Stmnts

Condensed Cons Balance Sheets

Condensed Cons Stmnts of Loss and Comprehensive Loss

Condensed Cons Stmnts of Stockh...

S3 - 2025-02-10 8-K Item1.01. Entry into a Material Definitive Agrmt.

Private Placement Offering

On February 10, 2025, Grace Therapeutics, Inc. (the Company), in connection with a private placement offering of the Companys securities (the Offering), entered into with certain institutional and ...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing - but what fun is that?
Response limited to 3 chars.

GRCE_IN_18 [2025-03-19 15:35:02 -0400] 2 Bytes | 2 tokens | Cum: 2997 tkns (37.46% of 8k)
==========================================================================

GRCE_OUT_19 [2025-03-19 15:35:04 -0400] 967 Bytes | 230 tokens | Cum: 3227 tkns (40.34% of 8k)
==========================================================================

Showing S1 (chunk 1 of 2): S1:
Item 2.02 Results of Operations and Financial Condition.

The following information is furnished pursuant to Item 2.02 "Results of Operations and Financial Condition."

On February 13, 2025, Grace Therapeutics, Inc. (formerly Acasti Pharma Inc.) issued a press release announcing its financial results for the fiscal quarter ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such fili

-- More? (MOR) or Next section? (NEX)

GRCE_IN_20 [2025-03-19 15:35:04 -0400] 3 Bytes | 2 tokens | Cum: 3229 tkns (40.36% of 8k)
==========================================================================

MOR

GRCE_OUT_21 [2025-03-19 15:35:08 -0400] 157 Bytes | 44 tokens | Cum: 3273 tkns (40.91% of 8k)
==========================================================================

Showing S1 (chunk 2 of 2): ng, except as expressly set forth by specific reference in such a filing or document....

-- More? (MOR) or Next section? (NEX)

GRCE_IN_22 [2025-03-19 15:35:08 -0400] 248 Bytes | 45 tokens | Cum: 3318 tkns (41.48% of 8k)
==========================================================================

I'm afraid there seems to be a misunderstanding. As a financial analyst, I'm equipped to provide insights on economic trends, assess investment strategies, or provide financial advice. Could you please provide more details or specify your question?

GRCE_OUT_23 [2025-03-19 15:35:27 -0400] 3164 Bytes | 776 tokens | Cum: 4094 tkns (51.18% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

The next section covers any insider trading.
If this section is blank, it's because there've been no recent filings.

Now we've reached the end of the analysis.
You are now allotted tokens to make a final analysis summary.
Please don't use tokens to explain why you didn't have enough information.
Save that for the survey that comes last.

Finish the summary with two scores: MARKET_SCORE[] and PRICE_TARGET[]

If you think there's a 90% likelihood of an upward moves, say: MARKET_SCORE[90]
If you think the high today will be 50% higher, add to the price. Eg., If the price is $5.00, add 50%: PRICE_TARGET[$7.50]
PRICE_TARGET is the highest it is expected to rise today, so it cannot be less than the current price.

After you have completed that, please provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-10 words headline for news story from first summary paragraph]

GRCE_IN_24 [2025-03-19 15:35:27 -0400] 1600 Bytes | 372 tokens | Cum: 4466 tkns (55.83% of 8k)
==========================================================================

The financial metrics presented shows a mixed bag. The previous closing was at 2.33 with a current price of 2.64, suggesting a positive change of 13.30%. The average trading volume stands at 83.27K with the most recent trading volume at 52,688 which is below the average. This suggests a lower interest from the market for this stock.

The Relative Strength Index (RSI) of 45.37 indicates the stock is near to its neutral point, neither oversold nor overbought. The moving averages indicate a downward trend with the 20-day, 50-day, and 200-day Simple Moving Average (SMA) at -2.14%, -18.33%, and -15.08% respectively. This indicates a bearish trend.

Despite a positive performance over the week (+14.78%), the company's performance over the quarter is negative (-26.26%). Sales in the past 5 years have decreased by 20%, and no recent sales growth is reported. Adding to this, the company is showing negative Return on Equity (ROE) and Return on Investment (ROI) indicating the company is not generating profits.

The market cap is relatively low at 36.21M and the number of outstanding shares is 10.14M. The company has a relatively high insider ownership at 26.94%, which can be seen as a positive sign of confidence from the management. There is no reported debt, which is a good sign.

Given these factors, the company seems to be in a tough spot with negative profitability and a downward trend. However, the positive change and insider ownership might give some hope.

MARKET_SCORE[45]
PRICE_TARGET[$2.90]

AI_RPT_HEADLINE: "Mixed Signals: High Insider Ownership Amid Negative Profitability"

GRCE_OUT_25 [2025-03-19 15:35:29 -0400] 561 Bytes | 131 tokens | Cum: 4597 tkns (57.46% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings & insider data
-> X3 <- Broader sector & market news
-> X4 <- General market sentiment & AI confidence levels
-> X5 <- AI's past analysis on similar companies
-> X6 <- More financial metrics
-> X7 <- AI's past analysis on this exact company
-> X8 <- Something altogether different (explain...)

GRCE_IN_26 [2025-03-19 15:35:29 -0400] 40 Bytes | 10 tokens | Cum: 4607 tkns (57.59% of 8k)
==========================================================================

-> X2 <- More SEC filings & insider data

GRCE_IN_27 [2025-03-19 15:35:30 -0400] 126 Bytes | 29 tokens | Cum: 4636 tkns (57.95% of 8k)
==========================================================================

====================================
[2025-03-19 12:35:30] # Analysis Completed
Elapsed Time: 67.81 seconds